Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.…
Talanx Q3 Earnings Call Highlights
Telix Pharmaceuticals (NASDAQ: TLX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,120 employees.
The shares were at 8.370 USD on 20 November 2026, down 7.4% over 52 weeks. Its 52-week range is 6.280 USD to 12.80 USD: the price is 34.6% below the high and 33.3% above the low.
At a market capitalisation of 2.84B USD, it trades at 83.7 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a premium of 153% for TLX.
Telix Pharmaceuticals reports return on equity of -1.7%, an operating margin of 6.2% and revenue up 22.3% year over year.
Its debt exceeds its cash by 327.95M USD, a debt-to-equity ratio of 1.12. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 4 analysts cover the stock; their mean price target of 19.37 USD is 131.4% above the current price.
No upcoming events tracked.